Abstract:In silico assessment of antibody developability during early lead candidate selection and optimization is of paramount importance, offering a rapid and material-free screening approach. However, the predictive power and reproducibility of such methods depend heavily on the selection of molecular descriptors, model parameters, accuracy of predicted structure models, and conformational sampling techniques. Here, we present a set of molecular surface descriptors specifically designed for predicting antibody developability. We assess the performance of these descriptors by benchmarking their correlations with an extensive array of experimentally determined biophysical properties, including viscosity, aggregation, hydrophobic interaction chromatography, human pharmacokinetic clearance, heparin retention time, and polyspecificity. Further, we investigate the sensitivity of these surface descriptors to methodological nuances, such as the choice of interior dielectric constant, hydrophobicity scales, structure prediction methods, and the impact of conformational sampling. Notably, we observe systematic shifts in the distribution of surface descriptors depending on the structure prediction method used, driving weak correlations of surface descriptors across structure models. Averaging the descriptor values over conformational distributions from molecular dynamics mitigates the systematic shifts and improves the consistency across different structure prediction methods, albeit with inconsistent improvements in correlations with biophysical data. Based on our benchmarking analysis, we propose six in silico developability risk flags and assess their effectiveness in predicting potential developability issues for a set of case study molecules.

What problem does this paper attempt to address?

### What problems does this paper attempt to solve? This paper aims to predict the developability of antibodies by introducing a series of molecular surface descriptors. Specifically, the research mainly focuses on the following problems: 1. **Improving prediction accuracy**: The prediction ability and reproducibility of existing computational methods in predicting antibody developability depend on the selected molecular descriptors, model parameters, the accuracy of the predicted structural model, and conformational sampling techniques. The author hopes to improve the accuracy and reliability of these predictions by introducing new molecular surface descriptors. 2. **Evaluating method sensitivity**: Researchers hope to evaluate the sensitivity of these molecular surface descriptors to different methodological details, including: - The choice of internal dielectric constant - The choice of hydrophobicity scale - Differences in structural prediction methods - The influence of conformational sampling 3. **Improving developability risk assessment**: By benchmarking a variety of experimentally determined biophysical properties (such as viscosity, aggregation, hydrophobic interaction chromatography, human pharmacokinetic clearance, heparin retention time, and multispecificity), researchers hope to improve the developability risk assessment method based on molecular surface descriptors. 4. **Proposing risk markers**: Based on the above analysis, the author proposes six in - silico risk markers for predicting potential developability problems and evaluates their effectiveness. ### Main content overview - **Background and importance**: The development of therapeutic antibodies has revolutionized the medical field, providing new treatment methods for various diseases such as cancer, autoimmune diseases, and infectious diseases. However, ensuring the effectiveness and success of these therapeutic antibodies requires considering their functional characteristics, binding affinity, and overall developability. Among them, the surface properties of antibodies have an important impact on their developability. - **Deficiencies in existing research**: Although the influence of structure - property relationships on developability has been widely studied, some factors leading to poor developability are still not fully understood. For example, extremely negative charges, extremely positive charges, and large hydrophobic regions may all cause different problems, but the specific effects of these properties need further exploration. - **Introduction of new methods**: The author introduced a set of molecular surface descriptors named MolDesk, which are specifically used to predict the developability of antibodies. These descriptors quantify the potential and hydrophobicity distribution on the antibody molecular surface by mapping surface properties such as charge distribution and hydrophobicity. - **Experimental verification and application**: Through the analysis of multiple experimental data sets, the author verified the performance of these descriptors in predicting viscosity, pharmacokinetic clearance, multispecificity, and aggregation. The results show that the new descriptors are superior to existing methods in some cases, and by averaging the conformational distribution, systematic偏差 can be reduced and the prediction consistency can be improved. ### Conclusion This study not only provides a new set of tools for in - silico prediction of antibody developability, but also deeply explores the influence of different methodological details on prediction results, providing valuable references for further optimizing and improving relevant prediction models.

Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling

PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning

Five computational developability guidelines for therapeutic antibody profiling

Structure, heterogeneity and developability assessment of therapeutic antibodies

DeepSP: Deep Learning-Based Spatial Properties to Predict Monoclonal Antibody Stability

In Silico Approaches to Deliver Better Antibodies by Design: The Past, the Present and the Future

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches

Binding symmetry and surface flexibility mediate antibody self-association

Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen

Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences

Developability considerations for bispecific and multispecific antibodies

Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics

Modeling and mitigation of high-concentration antibody viscosity through structure-based computer-aided protein design

Automated optimisation of solubility and conformational stability of antibodies and proteins

Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability

Evaluating Zero-Shot Scoring for In Vitro Antibody Binding Prediction with Experimental Validation

Antibody optimization enabled by artificial intelligence predictions of binding affinity and naturalness

Learned features of antibody-antigen binding affinity

Holistic in silico developability assessment of novel classes of small proteins using publicly available sequence-based predictors

Biophysical properties of the clinical-stage antibody landscape

Reduction of monoclonal antibody viscosity using interpretable machine learning